** U.S.-listed shares of Danish obesity drugmaker Novo Nordisk down 1.6% at about $133
** FDA staff said data showed use of Novo's long-acting weekly insulin had an increased risk of low blood sugar in patients with type 1 diabetes
** A panel of independent FDA advisers will meet on Friday to review and discuss the safety and effectiveness of company's insulin icodec — an under-the-skin injection
** The FDA is not obligated to follow the advisory panel's recommendations, but it usually does
** Separately, a large fire that broke out at a Novo office building in Denmark on Wednesday has been brought under control, the local fire department says
** Including session's fall, stock up ~28.5% YTD
(Reporting by Pratik Jain in Bengaluru)
((Pratik.Jain@thomsonreuters.com;))
Comments